A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Abroad (travel likely)RecruitingPHASE3
Conditions
Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Chinese Acadamy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, China
Contact: Principal Investigator (Min Yan, Ph.D)Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
Contact: Principal Investigator (Binghe Xu, Ph.D)
Study leads
Xianming Luo, Doctor
Study Director
Medical Director